Results 111 to 120 of about 2,404 (154)

Safety of nirsevimab in children aged 0-24 months: Analysis based on EudraVigilance data (2023-2025). [PDF]

Hum Vaccin Immunother
Morciano C, Annunziata A, Cutillo M, Mayer F, Spila Alegiani S.   +4 more
europepmc   +1 more source

Impact of nirsevimab universal prophylaxis on RSV bronchiolitis hospitalizations. A tertiary level children's hospital perspective

Introduction: The 2024–2025 winter season was the first in which Nirsevimab was adopted as universal prophylaxis for bronchiolitis in Friuli Venezia Giulia, a region in the northeastern Italy.
Amaddeo, Alessandro, Dal Cin, Margherita, Giangreco, Manuela, Cozzi, Giorgio, Fasiolo, Elena, Tonetto, Stefania, Comar, Manola, Nider, Silvia, Zappetti, Cristina, Cason, Carolina, Travan, Laura   +10 more
core   +1 more source

Effectiveness of Nirsevimab Reimmunization against Respiratory Syncytial Virus Hospitalization During the Second Season in High-Risk Children. [PDF]

J Pediatric Infect Dis Soc
Monge S, Núñez O, Pastor-Barriuso R, On Behalf Of The Nirsevimab Effectiveness Study Collaborators.   +3 more
europepmc   +1 more source

What is the Optimal RSV Immunization Strategy for Infants Born in the RSV Off-season? [PDF]

J Infect Dis
Moore HC, Foo D, Giannini F, Minney-Smith C, Blyth CC, Richmond PC, Effler P, Sarna M, STAMP RSV Investigators , the.   +9 more
europepmc   +1 more source

Mutational constraints on RSV F and its neutralization by antibodies. [PDF]

Nature
Simonich CAL, McMahon TE, Juviler G, Kampman L, Chu HY, Bloom JD.   +5 more
europepmc   +1 more source

Nirsevimab for respiratory syncytial virus prevention: A comprehensive product review. [PDF]

Hum Vaccin Immunother
Razzini JL, Martinon-Torres F.
europepmc   +1 more source

Detection of a Nirsevimab-Resistant RSV-B Variant (F:K68Q) in an Adult with Severe Infection. [PDF]

Infect Dis Ther
de Prost N, Le Goff M, Cappy P, Bay P, N'debi M, Soulier A, Pawlotsky JM, Rodriguez C, Fourati S.   +8 more
europepmc   +1 more source

Reply to Hodges et al. Comment on "Kura et al. Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. <i>Vaccines</i> 2026, <i>14</i>, 411". [PDF]

Vaccines (Basel)
Kura K, Lang JC, Wang D, Choi Y, Goveia MG, Sinha A, Chen YH, Elbasha EH.   +7 more
europepmc   +1 more source

Beyond Efficacy: Policy, Delivery, and Equity Determinants of Long-Acting Monoclonal Antibody Uptake for Infant RSV Prevention-A WAidid Consensus Document. [PDF]

Vaccines (Basel)
Esposito S, Abu-Raya B, Eley B, Halasa N, Martinon-Torres F, Mejias A, Spoulou V, Tenenbaum T, Torres JP, Osterhaus A, Ramilo O, Principi N.   +11 more
europepmc   +1 more source

Association between nirsevimab coverage and pediatric emergency department visits for bronchiolitis in 12 European countries: An interrupted time-series analysis. [PDF]

PLoS Med
Lenglart L, Titomanlio L, Alberti I, Almeida L, Aupiais C, Akyüz Özkan E, Barrett M, Basmaci R, Birbilen A, Borensztajn D, Schönenberger CB, Bressan S, Buonsenso D, Campos T, Castanhinha S, Chiaretti A, Claret G, De Zan F, Durnin S, Fodor L, Gomez B, Greber-Platzer S, Guedj R, Huege A, Leonard F, Maconochie IK, Marlow R, Milani G, Molina Gutierrez MA, Musolino AM, Oostenbrink R, Pucuka Z, Rivière S, Roland D, Rinder MR, Supino MC, Teksam O, Trenchs V, Valtuille Z, Vanda B, Vrijlandt S, Ouldali N, Nijman RG, EPISODES Study Group.   +43 more
europepmc   +1 more source